The use of chemotherapy in soft-tissue sarcomas

Oncologist

Volumn 7, Issue 4, 2002, Pages 348-359

  Spira, Alexander I ^a   Ettinger, David S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Chemotherapy; Doxorubicin; Ifosfamide; Soft tissue sarcomas

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IFOSFAMIDE; LIPOSOME; MESNA; MITOMYCIN; PACLITAXEL; TRABECTEDIN; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; HEMORRHAGIC CYSTITIS; HUMAN; LEUKOPENIA; MEDICAL DECISION MAKING; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REVIEW; SOFT TISSUE SARCOMA; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; RADIOTHERAPY, ADJUVANT; SARCOMA; SURGICAL PROCEDURES, ELECTIVE; TREATMENT OUTCOME;

EID: 0036061260     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-4-348     Document Type: Review

References (81)

1. Soft tissue sarcoma
2. Phase II evaluation of adriamycin in human neoplasia
3. Dose response evaluation of adriamycin in human neoplasia
4. Chemotherapy of advanced soft-tissue sarcomas in adults
5. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas
6. Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide
7. Proceedings: Combination chemotherapy for metastatic sarcoma
8. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas
9. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas
10. Grade 3 nausea, vomiting, and myelosuppression or progressive, metastatic sarcoma?
11. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy
12. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas
13. Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas
14. E.O.R.T.C. protocol for the therapy of metastatic soft tissue sarcoma, a randomized trial
15. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma
16. Cyvadic in advanced soft tissue sarcoma: A randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group
17. Cyclophosphamide versus ifosfamide: A randomized phase II trial in adult soft-tissue sarcomas
18. Ifosfamide and mesna: Response and toxicity at standard- and high-dose schedules
19. Prophylactic alkalization of the urine during cytostatic tumor treatment with the oxazaphosphorine derivatives, cyclophosphamide and ifosfamide
20. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: Preliminary results
21. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma
22. Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas
23. Response to ifosfamide and mesna: 124 Previously treated patients with metastatic or unresectable sarcoma
24. High-dose ifosfamide with mesna uroprotection: A phase I study
25. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion
26. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: A Southwest Oncology Group study
27. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas
28. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas
29. Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas
30. High-dose cisplatin for metastatic soft tissue sarcoma
31. Cisplatin. A phase II evaluation in previously untreated patients with soft tissue sarcomas
32. Cis-dichlorodiammineplatinum(II) in advanced soft tissue and bony sarcomas: A Southwest Oncology Group Study
33. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide
34. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma
35. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
36. High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies-dose-response and schedule dependence
37. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: The M.D. Anderson experience
38. The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: Early results from the EORTC Soft-Tissue and Bone Sarcoma Group
39. Granulocytemacrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
40. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS)
41. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas
42. Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas
43. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas
44. High-dose ifosfamide for soft tissue sarcomas: Set the scene, or senescence?
45. High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: Is it feasible?
46. Advanced soft tissue sarcoma: How many more trials with anthracyclines and ifosfamide?
47. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: Differences in clinical outcome and expression of multidrug resistance proteins
48. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: A Gynecologic Oncology Group study
49. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors
50. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications
51. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas
52. Gemcitabine in advanced stage soft tissue sarcoma: A phase II study
53. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: A phase II study
54. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
55. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation
56. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial
57. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group
58. Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas
59. Phase II trial of paclitaxel in patients with soft-tissue sarcoma
60. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face
61. Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: Results of a phase II trial
62. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
63. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
64. Ecteinascidin-743 (ET-743) induces durable responses and promising 1-year survival rates in soft tissue sarcomas (STS): Final results of phase II and pharmacokinetic studies in the USA
65. ET-743 is an active drug in adult soft-tissue sarcoma (STS): A STBSG-EORTC phase II trial
66. The role of multimodality therapy in soft-tissue sarcoma
67. Surgical treatment of 297 soft tissue sarcomas of the lower extremity
68. Soft tissue sarcoma. Integration of brachytherapy, resection, and external irradiation
69. The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy
70. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma
71. Is there no influence of local control on the rate of metastases in high-grade soft tissue sarcoma?
72. Limb-sparing surgery for soft tissue sarcomas: Wound related morbidity in patients undergoing wide local excision
73. Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas
74. Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma
75. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: Initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor
76. Radiation Therapy Oncology Group (RTOG) 95-14: A phase II study of neoadjuvant chemotherapy (CT) and radiation therapy (RT) in high risk (HR), high grade, soft tissue sarcomas (STS) of the extremities and body wall: A preliminary report
77. Adjuvant therapy for adult patients with soft tissue sarcomas
78. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: Meta-analysis of individual data
79. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized cooperative trial
80. Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: A prospective randomized feasibility trial
81. Adjuvant chemotherapy for adult soft tissue sarcoma: Is there a standard of care?